文献速递血液透析通路

长期抗凝患者接受瘘管造影的围手术期结局

Periprocedural Outcomes in Patients on Chronic Anticoagulation Undergoing Fistulograms.
PubMed 文献 · Ann Vasc Surg · 2020-05-13

一项回顾性单中心研究分析了2011至2017年长期服用华法林并接受瘘管造影的87例患者共175次手术,比较暂停华法林、继续华法林和肝素桥接三种策略的围手术期结局。结果显示三组在出血、血栓、通路再血栓和导管置入方面无显著差异,但肝素桥接组住院时间最长。继续华法林与较短住院时间相关,且不增加并发症。

要点

  • 继续华法林不增加出血或血栓并发症,且住院时间更短。
  • 肝素桥接未改善结局,反而延长住院时间。
  • 透析通路功能丧失需干预时,可考虑继续华法林。

核心结论

  • 继续华法林治疗与不增加并发症相关,且住院时间更短。

研究设计与样本

  • 回顾性单中心分析,纳入2011至2017年长期服用华法林并接受瘘管造影的87例患者共175次手术。

主要发现

  • 30天出血并发症在暂停华法林组、继续华法林组和肝素桥接组分别为5.7%、6.5%和8.3%(P=0.89)。
  • 30天系统性血栓并发症分别为3.8%、2.2%和0%(P=0.569)。
  • 通路再血栓分别为7.6%、13%和12.5%(P=0.517)。
  • 隧道透析导管置入分别为11.4%、13%和12.5%(P=0.958)。
  • 排除非通路相关住院后,住院时间在肝素桥接组为9.6±7.8天,暂停华法林组为2.6±5.9天,继续华法林组为1±2.8天(P<0.0001)。

临床怎么用

  • 对于接受瘘管造影的长期华法林抗凝患者,继续华法林可能是安全且能简化通路维护的选择。
  • 肝素桥接未显示结局优势,且与更长住院时间相关,应审慎使用。

局限性

  • 回顾性单中心设计,样本量有限,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of antithrombotic therapy with warfarin in patients undergoing fistulograms and possible interventions is controversial and difficult because of lack of adequate outpatient bridging options. Our goal was to assess periprocedural outcomes in patients managed using different anticoagulation strategies. METHODS: A retrospective, single-institution analysis of all patients on chronic anticoagulation with warfarin undergoing fistulograms from 2011 to 2017 was performed. Anticoagulation management strategies were classified as suspended warfarin (SW), continued warfarin (CW), and a heparin bridge with suspended warfarin (HB). Periprocedural outcomes were analyzed. RESULTS: There were 87 patients on chronic anticoagulation with warfarin who underwent 175 fistulograms. Median age was 63 years, and 43.4% were women. Indications for warfarin included atrial fibrillation (53%), prior pulmonary embolism/deep vein thrombosis (29%), and hypercoagulable state (14%). Distribution was SW (60%), CW (26%), and HB (14%). Approximately half (53%) were same-day procedures, 30% occurred during access-related admissions, and 14% were performed during nonaccess-related admissions. Common indications for a fistulogram included difficulty with dialysis (63.4%), access thrombosis (20.6%), and poor maturation (10.3%). Interventions included angioplasty (82.9%), thrombectomy/embolectomy (20.6%), and stenting (8.6%). Thirty-day outcomes for SW versus CW versus HB were similar for bleeding complications (5.7%, 6.5%, 8.3%; P = 0.89), systemic thrombotic complications (3.8%, 2.2%, 0%; P = 0.569), access rethrombosis (7.6%, 13%, 12.5%; P = 0.517), and tunneled dialysis catheter placement (11.4%, 13%, 12.5%; P = 0.958). After excluding procedures performed during a nonaccess-related admission, length of stay (LOS) was highest among HB (9.6 ± 7.8 days) compared with SW (2.6 ± 5.9 days) and CW (1 ± 2.8 days), (P < 0.0001). CONCLUSIONS: CW therapy in patients undergoing fistulograms was not associated with increased morbidity and was associated with shorter LOS. Bridging with heparin is not associated with improved outcomes, warranting a thorough consideration of continuing warfarin is safe and may streamline preservation of dialysis accesses without significantly increasing resource utilization.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Paredes LG, Arinze NV, Farber A, et al. Periprocedural Outcomes in Patients on Chronic Anticoagulation Undergoing Fistulograms. Ann Vasc Surg. 2020. PMID: 32416311. doi:10.1016/j.avsg.2020.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。